Clinical Validation of <i>PBRM1</i> Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
David A. Braun(Yale Cancer Center), Toni K. Choueiri(Harvard University), Catherine J. Wu(Dana-Farber Cancer Institute), Alice M. Walsh(BioScience Laboratories (United States)), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Sachet A. Shukla(Broad Institute), Yuko Ishii(Bristol-Myers Squibb (United States))
Cited by 242
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k